These findings indicate that although ACE2 is not associated with prognosis, in most cancers, it is significantly associated with immune penetration levels in a variety of tumors (especially patients with lung and breast cancer) including CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and DC. This evidence concerns the gene CD8A and cancer.